Sumitomo Dainippon Gains Asian Rights to Poxel’s Late-Stage Diabetes Drug
By Natasha Piper
Pharma Deals Review: Vol 2017 Issue 11 (Table of Contents)
Published: 22 Nov-2017
DOI: 10.3833/pdr.v2017.i11.2285 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Merck Serono spin-off, Poxel, has entered into a strategic partnership with Sumitomo Dainippon Pharma for the development and commercialisation of imeglimin, a Phase III-ready therapy in development for the treatment of type 2 diabetes, in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS